Dr Sharon Cohen joins touchNEUROLOGY to discuss the challenges in diagnosing Alzheimer’s disease (AD) at an early stage, the most exciting recent developments in diagnostic criteria, genetic testing, and neuroimaging techniques. Dr Cohen also talks through the recent developments in biomarker strategies for diagnosis and precision management of early AD.
The presentation entitled: ‘Accelerating Progress in Alzheimer’s Treatment. How Can we achieve timely, accurate, neuropathological diagnosis and precision management in early AD?’ was presented at the International Conference of Alzheimer’s and Parkinson’s diseases and related neurological disorders (AD/PD), 13-15 October 2021.
Questions:
- What are the challenges in diagnosing Alzheimer’s disease (AD) at an early stage, and how can these be overcome? (0:20)
- What have been the most exciting recent developments in diagnostic criteria, genetic testing, neuroimaging techniques, and neurochemical assays? (1:23)
- What have we learned about biomarker strategies for diagnosis and precision management of early AD? (3:23)
Disclosures: Sharon Cohen is a consultant for but receives no personal fees from Alnylam, Biogen, Novo Nordisk, and RetiSpec; and receives grant/research support paid to institution from AgeneBio, Alector, Alnylam, Anavex, Biogen, Cassava Neurosciences, Eisai, Eli Lilly, Green Valley, Janssen, Novo Nordisk, RetiSpec, Roche, UCB Biopharma, and Vielight. Sharon Cohen is also on the advisory board (receives no personal fees) for Biogen, Cassava Neurosciences, Cognivue, Cogstate, Eisai, Eli Lilly, INmune Bio, ProMIS Neurosciences, and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of AD/PD 2022
